Autologous Bone Marrow Transplantation - Blog Science Connections

Chemopurging 149
4-HC + VCR IC75 AML + ALL
LEVEL 2
t!
MAC ALL
MAC AML
MAC ALL
4-HC + VCR IC75 4-HC + VCR IC7 5
4,
4,
MAC AML
4-HC + VCR IC90
MAC ALL
4-HC + VCR IC90
Figure 2. Phase I studies of hematopoietic recovery (sequential) (4-HC, 4-hydroperoxycyclophosphamide;
VCR, vincristine; IC, inhibitory concentration; AML, acute
myeloid leukemia; MAC, magnetic affinity colloid).
plan to introduce chemopurging with immunomagnetic separation initially at
the IC 75
dose level. If there are no significant toxicity or engraftment
problems, the ex vivo chemotherapy dose will then be raised to IC 90
levels.
The arrows in Figure 2 show how modifications will be made at each step until
a pool of MAbs with acceptable toxicity to normal precursor cells in
combination with 4-HC and VCR is selected. In this way, an effective ex vivo
marrow purging regimen for leukemia may be developed.
ACKNOWLEDGMENT
This work was supported in part by National Cancer Institute grants POl
CA23077 and ROI CA31536, and by the Susan G. Komen Foundation.
REFERENCES
1. Kaizer H, Chow HS. Cancer Invest 1984,2:203.
2. Kaizer H, Santos GW. In Progress in Clinical Cancer, Ariel I, ed. Grune & Stratton, New York,
1982:31.
3. Sharkis SJ, Santos GW, Colvin M. Blood 1980;55:521.
4. Gorin NC, Douay L, Laporte JP, Lopez M, Mary JY, Najman A, Salmon C, Aegerter P,
Stachowiak J, David R, Pene F, Kantor G, Deloux J, Duhamel E, van den Akker J, Gerota J,
Parlier Y, Duhamel G. Blood 1986:67:1367.